Cite
MLA Citation
Francisco Bravo et al.. “Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.” Clinical and translational gastroenterology, vol. 12, no. 2, 2021, pp. e00298–. http://access.bl.uk/ark:/81055/vdc_100167916051.0x000024